Patent ID: 9211321
Filing Date: 2015-12-15
Classification: A61K,A61P

Abstract:
1. An in vitro method for priming of target T cells comprising antigen specific T helper 1 (Th1) cells or cytotoxic T cells (CTLs) suitable for administration to a patient having a tumor, said method comprising co-culturing (1) target T cells from the patient to be treated, (2) monocyte-derived dendritic cells from a first healthy donor, (3) autologous or allogeneic tumor material or tumor associated proteins or peptides, and (4) allogeneic lymphocytes obtained by a mixed leukocyte reaction comprising culturing inactivated antigen presenting cells (APCs) from the first healthy donor with peripheral blood mononuclear cells (PBMCs) from a second healthy donor, wherein the APCs express at least one MHC class II antigen that is identical with an MHC class II antigen expressed on APCs from the patient to be treated, and wherein the allogeneic lymphocytes are sensitized against the APCs from the first healthy donor, wherein the sensitized allogeneic lymphocytes promote increased proliferation and/or survival of the antigen-specific Th1 cells or CTLs.